PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 26, 2023BMC Cardiovascular Disorders2 citationsOpen Access

Coronary embolism due to probable clinical bioprosthetic aortic valve thrombosis: a case report

RARoshan A. AnandaZZZhihua Zhang

Key Result

Warfarin therapy normalized the raised transaortic mean pressure gradient from 22 mmHg to 13 mmHg after eight weeks in a patient with coronary embolism due to probable bioprosthetic valve thrombosis.

Study Design

Type

Case Report (n=1)

Structured PICO

P
Population
A 64-year-old male with a history of bioprosthetic aortic valve replacement who presented with NSTEMI secondary to coronary embolism and probable bioprosthetic valve thrombosis, followed for 39 months.
I
Intervention
Warfarin therapy (target INR 2-3) with enoxaparin bridging, continued lifelong.
O
Outcome
Resolution of raised transaortic gradient and clinical wellness at follow-up.

Early moderate-to-severe hemodynamic valve deterioration in bioprosthetic valves warrants investigation for thrombosis and consideration of anticoagulation to prevent rare but severe thromboembolic events like coronary embolism.

Limitations

  • Absence of histopathology to definitively confirm the diagnosis
  • Cardiac computed tomography was not performed on presentation to assess valve morphology
  • Lack of histopathology to definitively confirm the diagnosis of bioprosthetic valve thrombosis
  • Single case report

Abstract

BACKGROUND: Coronary embolism is a relatively rare but important non-atherosclerotic cause of acute coronary syndrome, mainly caused by atrial fibrillation and mechanical heart valve thrombosis due to subtherapeutic anticoagulation. There have been increasing reports of bioprosthetic valve thrombosis (BPVT), but thromboembolic events are rare and mainly affect the cerebrovascular system. Coronary embolism is an extremely rare complication of BPVT. CASE PRESENTATION: A 64-year-old male presented with non-ST-Elevation myocardial infarction (NSTEMI) to an Australian regional health service. Three years ago, he had undergone Bentall procedure with bioprosthetic aortic valve replacement for severe aortic regurgitation and significant aortic root dilatation. Diagnostic coronary angiography revealed embolic occlusion of first diagonal branch in the absence of underlying atherosclerosis. Prior to NSTEMI presentation, the patient was clinically asymptomatic apart from the progressive increase in transaortic mean pressure gradient on transthoracic echocardiography which was first detected seven months after surgical aortic valve replacement. Transoesophageal echocardiography showed restrictions of the aortic leaflet opening but no evidence of mass or vegetation. After eight weeks of warfarin therapy, the raised aortic valve gradient returned to normal. Lifelong warfarin was prescribed, and patient remained clinically well at 39-month follow-up. CONCLUSION: We experienced a case of coronary embolism in a patient with probable BPVT. Reversible bioprosthetic valve hemodynamic deterioration after anticoagulation strongly supports the diagnosis in the absence of histopathology. Early moderate-to-severe hemodynamic valve deterioration warrants further investigations, including cardiac computed tomography and sequential echocardiography, to investigate for probable BPVT and consideration of timely anticoagulation initiation to prevent thromboembolic events.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ananda et al. (2023) conducted a case report in Coronary embolism and probable bioprosthetic aortic valve thrombosis (n=1). Warfarin was evaluated on Transaortic mean pressure gradient (MPG). Warfarin therapy normalized the raised transaortic mean pressure gradient from 22 mmHg to 13 mmHg after eight weeks in a patient with coronary embolism due to probable bioprosthetic valve thrombosis.

synapsesocial.com/papers/6a730eafea5327a145f5c792https://doi.org/10.1186/s12872-023-03359-9
Ask AI
Helpful
Bookmark
Share
View Full Paper